Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Phase IV Study of Levornidazole and Sodium Chloride Injection for Intra-abdominal Anaerobic Infections
CTR20260916Phase 4Active
- Sponsor
- Shijiazhuang No. 4 Pharmaceutical
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of levornidazole in amebiasis, postoperative anaerobic infection, Intra-abdominal infection (IAI), suppurative cholangitis (ASC), hepatic abscess, sponsored by Shijiazhuang No. 4 Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
levornidazole
03
Conditions
amebiasispostoperative anaerobic infectionIntra-abdominal infection (IAI)suppurative cholangitis (ASC)hepatic abscess
Beyond the preview
Go deeper on CTR20260916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260916.